The blue light-induced retinal degeneration model mirrors retinal degeneration in human diseases, including age-related macular degeneration (AMD), retinal detachment, and retinitis pigmentosa (RP). As one of the global leaders in ocular disease solutions, Ace Therapeutics has developed a rodent blue light injury model for our global customers, which simulates human retinal degeneration and neuroinflammation. Here, you will benefit from our team of experienced experts to facilitate the development of your upcoming therapy.
Retinal degeneration includes hereditary and complex retinal degeneration. In many ocular diseases that lead to blindness, degeneration of retinal nerve cells is the main factor leading to vision loss. In these cases, the photoreceptors become dysfunctional and/or slowly destroyed. In recent years, many studies have shown that light-induced oxidative stress may harm the retina, leading to degenerative diseases such as age-related macular degeneration. In rodents, a major feature of light-induced retinal degeneration is the death of apoptotic photoreceptors cells, thus, it can mimic human retinal disease clinicopathology. In particular, the blue light-induced retinal degeneration model also allows the study of cellular (retinal pigment epithelial (RPE) cell) responses in localized retinal regions (hot spots).
Fig. 1. Retinal cell death after blue light exposure. (Geiger P, et al., 2015)
Photoreceptor cell death causes a variety of retinal degenerative diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Light exposure is a standardized method for simulating photoreceptor degeneration in human diseases. In order to reflect the symptoms of retinal degeneration, Ace Therapeutics has developed a rodent blue light injury model. This is an animal model that mimics human retinal degeneration and neuroinflammation. It can be used to study cell death mechanisms and the neuroprotective properties of candidate compounds.
Ace Therapeutics rodent blue light injury model is widely used by clients to study retinal protective therapies against photoreceptor loss. To meet different researchers' needs, our talented scientists provide the following two rodent blue light injury models.
Ace Therapeutics' research team expose BALB/c mice or SD rats to blue light (λ = 450 nm ± 15 nm) for 6 hours to induce retinal degenerative changes. This process is monitored visually through optical coherence tomography (OCT) and histopathologically.
Ace Therapeutics also provides efficacy evaluation services for candidate compounds and judges endpoints by monitoring the thickness of the outer retinal nuclear layer (ONL) in the following way.
Ace Therapeutics has accumulated rich experience and scientific data in retinal degeneration model construction. In order to better promote customers' preclinical project research, we can also provide pharmacodynamic evaluation solutions for ophthalmic products or novel therapies. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!
References